Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir—the company’s twice-yearly ...

Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving ...

Chiedza Makura only learned she had been dismissed from her nursing job when a WhatsApp message came through on the evening of January 28. The 37-year-old single mother of three worked as an HIV nurse ...

Several important steps should be taken and/or considered after the identification of an oral cavity lesion: Perform a ...

Defibrotide prophylaxis after HSCT did not reduce sinusoidal obstructive syndrome incidence in high-risk pediatric patients, per retrospective study at 2025 Tandem Meeting.

Harare - The abrupt cessation of USAID funding, a direct consequence of the implementation of former U.S. President Donald ...

Experts discuss PPI use for GI protection in patients on antithrombotics, highlighting risk factors, dosing, drug ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/19.CcrFU5Zy.js ...

CSL and uniQure's Hemgenix shows sustained efficacy in hemophilia B, reducing bleeding rates by 90% and eliminating ...

Data from the study showed that HEMGENIX continues to deliver sustained factor IX activity levels for up to four years post-treatment. The treatment also provides long-term bleed protection, ...

Medications are the mainstay of treatment for multiple sclerosis (MS). Many of them are used to block the immune system's attack on the nerves and slow or prevent progression and relapses (flare-ups) ...

The Clinical Guidelines Committee of the American College of Physicians (ACP) has released a new clinical guideline on the prevention of episodic migraine headache in nonpregnant adults in the ...